GLP1_NEW
Efsubaglutide alfa injection
EFSUBA_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.04 (-1.72 to -0.34) | 0.74 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.79 (-5.29 to 1.89) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.48 (0.01 to 30.13) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.45 (0.01 to 30.17) | 0.62 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.41 (-11.92 to 10.54) | 0.43 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.00 (0.28 to 3.56) | 0.50 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.95 (0.12 to 7.07) | 0.60 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.87 (0.61 to 6.21) | 0.46 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.37 (1.47 to 24.29) | 0.23 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 6.68 (2.71 to 17.87) | 0.06 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.94 (0.49 to 8.69) | 0.36 |